~~<i id='D1F5D8D5A0'><strike id='D1F5D8D5A0'><tt id='D1F5D8D5A0'><pre id='D1F5D8D5A0'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

comprehensive

author：comprehensive 2025-09-03 09:37:40 - browse：71976

Stoke Therapeutics is still seeking an effective dose for an experimental drug to treat a severe form of childhood epilepsy, following the release of updated data Tuesday that showed disappointing reductions in convulsive seizure activity.

In the latest look at an ongoing mid-stage study, three monthly injections of the Stoke drug, called STK-001, given at a 45-mg dose, resulted in a median 18% reduction in convulsive seizure activity, compared to baseline.

The new analysis was conducted on 16 children diagnosed with a rare form of epilepsy called Dravet syndrome. Last November, in six patients, the drug showed a median 55% reduction in seizure activity.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： Change Healthcare payments predicted restored March 15

hotspot

leisure time

entertainment

focus

knowledge

Illustration:ChristineKao/STAT;Photos:Getty,Adobe,AP,CDCandNIAIDTenweeksaftergovernmentscientistsdis

WSS

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

Novo Nordisk obesity pill bests Wegovy in early trial

The drug industry has found itself all alone in Washington

Anthony Fauci pushes back on GOP claims during Covid hearing

The problem with charging patients to message their doctors

Structure Therapeutics oral GLP

focus

comprehensive

hotspot

Anesthesiologist group: stop taking Ozempic before surgery

First medicine developed to treat MASH expected to be approved soon

Malaria cases in Florida and Texas: Here’s what you need to know

Former medical device CEO who sold dummy, plastic parts convicted of fraud

Drug repurposing or repositioning? The language matters

Sen. Paul opposes bill to ban Chinese biotechs

ChatGPT in medicine: STAT answers readers' burning questions

First medicine developed to treat MASH expected to be approved soon

Hollywood unions extend contract negotiations for actors

Elevance PBM president out as customers face prescription chaos

leisure time

ASCO Daily Recap: CAR

UnitedHealth CEO's Medicaid comments send insurer stocks diving

ASCO Daily Recap: CAR

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Change Healthcare cyberattack prompts Medicare loan program

Sen. Paul opposes bill to ban Chinese biotechs

entertainment

focus

focus

knowledge